Prothena Corporation plc, a clinical-stage neuroscience company, focuses on discovery and development of novel therapies for life-threatening diseases in the United States.
Excellent balance sheet and slightly overvalued.
Share Price & News
How has Prothena's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: PRTA's share price has been volatile over the past 3 months.
7 Day Return
1 Year Return
Return vs Industry: PRTA underperformed the US Biotechs industry which returned 1.6% over the past year.
Return vs Market: PRTA underperformed the US Market which returned -10.7% over the past year.
Price Volatility Vs. Market
How volatile is Prothena's share price compared to the market and industry in the last 5 years?
Simply Wall St News
4 weeks ago | Simply Wall StIs Prothena Corporation plc's (NASDAQ:PRTA) CEO Paid Enough Relative To Peers?
1 month ago | Simply Wall StDoes This Valuation Of Prothena Corporation plc (NASDAQ:PRTA) Imply Investors Are Overpaying?
2 months ago | Simply Wall StHere's Why We're Not Too Worried About Prothena's (NASDAQ:PRTA) Cash Burn Situation
Is Prothena undervalued compared to its fair value and its price relative to the market?
Undervalued compared to fair value
Share Price vs. Fair Value
Below Fair Value: PRTA ($10.7) is trading below our estimate of fair value ($11.37)
Significantly Below Fair Value: PRTA is trading below fair value, but not by a significant amount.
Price To Earnings Ratio
PE vs Industry: PRTA is unprofitable, so we can't compare its PE Ratio to the Biotechs industry average.
PE vs Market: PRTA is unprofitable, so we can't compare its PE Ratio to the US market.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate PRTA's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: PRTA is good value based on its PB Ratio (1.6x) compared to the US Biotechs industry average (2.6x).
How is Prothena forecast to perform in the next 1 to 3 years based on estimates from 7 analysts?
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: PRTA is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: PRTA is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: PRTA is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: PRTA's revenue (52.8% per year) is forecast to grow faster than the US market (7.2% per year).
High Growth Revenue: PRTA's revenue (52.8% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if PRTA's Return on Equity is forecast to be high in 3 years time
How has Prothena performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: PRTA is currently unprofitable.
Growing Profit Margin: PRTA is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: PRTA is unprofitable, and losses have increased over the past 5 years at a rate of -13.2% per year.
Accelerating Growth: Unable to compare PRTA's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: PRTA is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (22%).
Return on Equity
High ROE: PRTA has a negative Return on Equity (-28.46%), as it is currently unprofitable.
How is Prothena's financial position?
Financial Position Analysis
Short Term Liabilities: PRTA's short term assets ($378.4M) exceed its short term liabilities ($17.7M).
Long Term Liabilities: PRTA's short term assets ($378.4M) exceed its long term liabilities ($128.6M).
Debt to Equity History and Analysis
Debt Level: PRTA is debt free.
Reducing Debt: PRTA has not had any debt for past 5 years.
Inventory Level: PRTA has a low level of unsold assets or inventory.
Debt Coverage by Assets: Insufficient data to determine if PRTA's debt is covered by short term assets.
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: PRTA has sufficient cash runway for more than 3 years based on its current free cash flow.
Forecast Cash Runway: Insufficient data to determine if PRTA has enough cash runway if its free cash flow continues to grow or shrink based on historical rates.
What is Prothena's current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Notable Dividend: Unable to evaluate PRTA's dividend yield against the bottom 25% of dividend payers, as the company has not reported any payouts.
High Dividend: Unable to evaluate PRTA's dividend yield against the top 25% of dividend payers, as the company has not reported any payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if PRTA's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if PRTA's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of PRTA's dividend in 3 years as they are not forecast to pay a notable one for the US market.
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Gene Kinney (50yo)
Mr. Gene G. Kinney, Ph.D., has been the Chief Executive Officer and President of Prothena Corporation plc since September 26, 2016 and October 3, 2016 respectively and served as its Chief Operating Officer ...
CEO Compensation Analysis
Compensation vs Market: Gene's total compensation ($USD11.40M) is above average for companies of similar size in the US market ($USD2.13M).
Compensation vs Earnings: Gene's compensation has increased whilst the company is unprofitable.
|CFO & COO||7.08yrs||US$4.96m||0.0080% $35.2k|
|Chief Scientific Officer||2.83yrs||US$3.34m||no data|
|Chief Regulatory Officer||3.33yrs||US$3.44m||no data|
|Chief Accounting Officer & Controller||6.92yrs||no data||no data|
|Chief Legal Officer & Company Secretary||0.75yr||no data||no data|
|Head of Communications||no data||no data||no data|
|Chief Development Officer||2.25yrs||no data||no data|
|Chief Business Officer||0.083yr||no data||no data|
Experienced Management: PRTA's management team is considered experienced (2.8 years average tenure).
|Independent Director||7.08yrs||US$217.42k||no data|
|Independent Director||7.33yrs||US$221.42k||0.0031% $13.4k|
|Independent Chairman||7.33yrs||US$238.42k||0.00061% $2.7k|
|Independent Director||7.33yrs||US$222.42k||no data|
|Independent Director||6.75yrs||US$222.42k||0.011% $46.2k|
|Independent Director||5.25yrs||US$207.42k||no data|
|Independent Director||0.75yr||no data||no data|
|Independent Director||0.33yr||no data||no data|
Experienced Board: PRTA's board of directors are considered experienced (6.8 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.
Prothena Corporation plc's company bio, employee growth, exchange listings and data sources
- Name: Prothena Corporation plc
- Ticker: PRTA
- Exchange: NasdaqGS
- Founded: 2012
- Industry: Biotechnology
- Sector: Pharmaceuticals & Biotech
- Market Cap: US$438.626m
- Shares outstanding: 39.91m
- Website: https://www.prothena.com
Number of Employees
- Prothena Corporation plc
- 77 Sir John Rogerson’s Quay
- Block C
- Co. Dublin
|Ticker||Exchange||Primary Security||Security Type||Country||Currency||Listed on|
|PRTA||NasdaqGS (Nasdaq Global Select)||Yes||Ordinary Shares||US||USD||Dec 2012|
|0PT||DB (Deutsche Boerse AG)||Yes||Ordinary Shares||DE||EUR||Dec 2012|
|0Y3M||LSE (London Stock Exchange)||Yes||Ordinary Shares||GB||USD||Dec 2012|
Prothena Corporation plc, a clinical-stage neuroscience company, focuses on discovery and development of novel therapies for life-threatening diseases in the United States. The company is involved in developing PRX002/RG7935 that is in Phase II clinical trial for treating Parkinson’s disease and other related synucleinopathies; and PRX004, a antibody that is in Phase I clinical trial for the treatment of ATTR amyloidosis. Its discovery-stage programs include Tau for treating Alzheimer's disease, progressive supranuclear palsy, frontotemporal dementia, chronic traumatic encephalopathy, and other tauopathies; Aß, or Amyloid Beta, a protein for the treatment of Alzheimer’s disease; TDP-43 for amyotrophic lateral sclerosis and frontotemporal dementia; and other products for neurodegeneration. The company has a license, development, and commercialization agreement with F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc. to develop and commercialize antibodies that target alpha-synuclein; and a collaboration agreement with Celgene Corporation to develop antibodies. Prothena Corporation plc was founded in 2012 and is based in Dublin, Ireland.
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2020/04/02 01:26|
|End of Day Share Price||2020/04/01 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.